Online Trial Tracker - Larvol Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

oxaliplatin / Generic mfg.

NCT05447715: Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer

Not yet recruiting

134

RoW

Fruquintinib

Weijian Guo

Metastatic Colorectal Cancer

12/24

01/25

NCT05630183: A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer

Recruiting

Botensilimab, AGEN1181, Gemcitabine, Nab-paclitaxel

Agenus Inc.

Metastatic Pancreatic Ductal Adenocarcinoma

12/24

NCT05864755: HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma

Recruiting

RoW

HAIC+Durvalumab+Tremelimumab+Bevacizumab

Tianjin Medical University Cancer Institute and Hospital

Unrescetable Hepatocellular Carcinoma

12/24

12/25

OPTICAL-2, NCT05571644: Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer

Recruiting

143

RoW

mFOLFOXIRI + Cadonilimab, Oxaliplatin, Irinotecan, 5-Fluorouracil, Leucovorin, Cadonilimab (AK104), mFOLFOX6, mFOLFOXIRI

Sun Yat-sen University

Colorectal Cancer

12/24

12/25

DUREC, NCT04293419: Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer

Recruiting

Europe

Durvalumab (MEDI4736)

Grupo Espanol Multidisciplinario del Cancer Digestivo, AstraZeneca, Vall d'Hebron Institute of Oncology (VHIO)

Rectal Cancer

12/24

03/25

AMBITION, NCT04625803: Neoadjuvant Therapy for Locally Advanced Colon Cancer

Recruiting

RoW

Camrelizumab , apatinib and chemotherapy

Zhejiang University

Colon Cancer, Neoadjuvant Therapy

12/24

11/25

NCT01941641: Colon Neoadjuvant FOLFOXIRI Study

Active, not recruiting

RoW

neoadjuvant FOLFOXIRI, Capecitabine

Chinese University of Hong Kong

Rectal Cancer

12/25

12/26

NCT03784326: Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma

Recruiting

Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Conventional Surgery, Fluorouracil, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Tiragolumab

M.D. Anderson Cancer Center, National Cancer Institute (NCI)

Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage II Esophageal Adenocarcinoma AJCC v8, Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8

12/24

NCT04084496: mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients

Recruiting

RoW

Folfirinox

Sun Yat-sen University

Pancreatic Cancer

12/24

SOLAR, NCT05673772: Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer

Recruiting

364

RoW

short-course radiotherapy, mFOLFOX6, Chemoradiotherapy, TME surgery

Kyungpook National University Hospital, National Cancer Center, Korea

Rectal Cancer

12/24

12/29

HOLIPANC, NCT04617457: Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas

Recruiting

150

Europe

nal-irinotecan (nal-iri) (Onyvide), oxaliplatin (ox), 5-fluouracil (5-FU), folinic acid (FA), nal-irinotecan (nal-iri), oxaliplatin (ox), 5-fluouracil (5-FU), folinic acid (FA), ONIVYDE TM

University of Cologne, Servier

Pancreatic Cancer, Metastasis, Surgery, Oligometastatic Disease

12/24

09/25

LOTS, NCT04999332: Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 () For Locally Advanced Gastric or Gastroesophageal Junction Cancer

Recruiting

RoW

leucovorin, oxaliplatin, docetaxel, S-1, leucovorin (Folina tab, TTY Biopharm, TW), oxaliplatin (Oxalip, TTY Biopharm, TW), docetaxel (Taxotere, Sanofi-Aventis, FR), S-1 (TS-1, Taiho, JP)

National Cheng-Kung University Hospital, TTY Biopharm, Kaohsiung Veterans General Hospital., Taipei Veterans General Hospital, Taiwan, China Medical University Hospital

Gastric Cancer, Gastric Adenocarcinoma, Effects of Chemotherapy, Toxicity Due to Chemotherapy

12/24

12/25

NCT05026905: A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer

Recruiting

RoW

Gemcitabine 1000 mg, Gemcitabine, Nab paclitaxel, nab-paclitaxel, S1, S-1, leucovorin, Calcium Folinate tablet, Oxaliplatin

National Health Research Institutes, Taiwan, China Medical University Hospital, National Cheng-Kung University Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital, Taichung Veterans General Hospital

Phase II, Open-label, Parallel 2-arm, Multi-center

12/24

12/27

ChiCTR2100054181: An exploratory clinical study of camrelizumab combined with chemotherapy in the first-line treatment of MSI-H/dMMR advanced gastric cancer

Not yet recruiting

106

Camrelizumab + Oxaliplatin + 5-FU or Capecitabine or Tegafur

Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital, Self-funded

MSI-H/dMMR advanced gastric cancer

NCT05176964: Chemotherapy and Tislelizumab With Split-course HFRT for Locally Advanced Rectal Cancer

Recruiting

RoW

split-course HFRT, hypofraction radiotherapy, CAPOX chemotherapy, oxaliplatin and capecitabine, Tislelizumab, immunotherapy

Fujian Medical University Union Hospital

Rectal Cancer, Radiation Oncology

12/24

12/25

NCT05601479: Preventive Effect of Acetyl-L-carnitine on Oxaliplatin-induced Peripheral Neuropathy

Not yet recruiting

100

RoW

Acetyl-L-carnitine, Chinese Food and Drug Administration H20180021

Nanfang Hospital of Southern Medical University

Acetylcarnitine, Chemotherapy-induced Peripheral Neuropathy

12/24

ChiCTR2200065278: Preventive Effect of Acetyl-L-carnitine on Oxaliplatin-induced Peripheral Neuropathy：A Randomized, Controlled, Open-label, Phase 2 Trail

Not yet recruiting

100

At the beginning of the first chemotherapy of the oxaliplatin regimen, acetyl levocarnitine 500mg was given orally three times daily for 24 weeks. If the subjects discontinued oxaliplatin-containing chemotherapy for various reasons (such as oxaliplatin-allergy, etc.), the subjects were required to continue taking acetyl-L-carn ;None

Nanfang Hospital, Southern Medical University; Nanfang Hospital, Southern Medical University, Nanfang Hospital, Southern Medical University Clinical Research Project

Oxaliplatin induced peripheral neuropathy，OIPN

RECMULRA-TNT, NCT05858567: Total Neoadjuvant Therapy With Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Ultra Low Rectal Adenocarcinoma

Recruiting

RoW

Envafolimab

Sir Run Run Shaw Hospital

Rectal Cancer

12/24

06/25

NCT05841134: Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer

Not yet recruiting

Tislelizumab, Capecitabine, Oxaliplatin

The First Affiliated Hospital of Zhengzhou University

MSI-H Colorectal Cancer, Tislelizumab, Oxaliplatin, Capecitabine

12/24

01/27

NCT05872841: H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis

Not yet recruiting

Recombinant human adenovirus type 5 + TACE, H101+TACE

Tianjin Medical University Cancer Institute and Hospital

Primary Hepatocellular Carcinoma, Portal Vein Thrombosis

12/24

06/25

NCT06054906: Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric Cancer

Recruiting

RoW

sintilimab+metronomic PLOF

Huashan Hospital

Gastric Cancer

12/24

12/25

INTERACT-II, NCT06003998: Intraperitoneal Irinotecan With Concomitant FOLFOX and Bevacizumab

Recruiting

Europe

Irinotecan, Intraperitoneal irinotecan, FOLFOX regimen, 5-FU + oxaliplatin, Bevacizumab, Avastin

Catharina Ziekenhuis Eindhoven

Colorectal Cancer, Peritoneal Metastases

01/25

NCT05982301: Sintilimab Combined With Modified FLOT Regimen in the Treatment of Metastatic Gastric Cancer

Recruiting

RoW

Sintilimab, paclitaxel-albumin, oxaliplatin, 5-FU, Sintilimab+mFLOT

Fudan University

Gastric Cancer, Chemotherapy Effect, Immune Checkpoint Inhibitor

01/25

12/25

NCT05948449: To Evaluate the Efficacy and Safety of Cadonilimab With SOX as Neoadjuvant Therapy for Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Not yet recruiting

S-1, Oxaliplatin, Cadonilimab

Sichuan University

Gastric Cancer

01/25

07/25

NCT05945823: Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Recruiting

Europe, US

Futibatinib, TAS-120, Pembrolizumab, MK-3475, KEYTRUDA®, Cisplatin, PLATINOL®, 5-FU, ADRUCIL®, Oxaliplatin, ELOXATIN®, Leucovorin, calcium folinate, folinic acid, WELLCOVORIN®, Levoleucovorin, calcium levofolinate, levofolinic acid, FUSILEV®, Irinotecan

Taiho Oncology, Inc.

Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Siewert Type 1 GEJ Cancer, Pancreatic Cancer

01/25

05/25

ComboMATCH Treatment Trial, NCT05564403: Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A )

Recruiting

Binimetinib, ARRY-162, ARRY-438162, MEK162, Mektovi, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669

National Cancer Institute (NCI)

Recurrent Biliary Tract Carcinoma, Recurrent Distal Bile Duct Adenocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Hilar Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Hilar Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Biliary Tract Carcinoma, Unresectable Distal Bile Duct Adenocarcinoma, Unresectable Gallbladder Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma

01/25

NCT05715931: Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Recruiting

RoW

Toripalimab, Trastuzumab, 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT)

Yu jiren

Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, HER2-positive Gastric Cancer

03/25

03/28

NCT05815303: XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer

Recruiting

RoW

Cadonilimab, Oxaliplatin, Capecitabine

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Rectal Cancer, MSS

03/25

03/26

ChiCTR2200057726: TACE and thermal ablation combined with anti-angiogenic drugs, immune checkpoint inhibitors and chemotherapy in the treatment of liver metastases from gastric cancer: a single-center, single-arm prospective clinical study

Not yet recruiting

TACE+thermal ablation+apatinib +sintilimab +Oxaliplatin+Tegafur

Shandong First Medical University Affiliated Provincial Hospital; Shandong First Medical University Affiliated Provincial Hospital, NA

Gastric cancer with liver metastasis

NCT05774964: Quintuple Method for Treatment of Multiple Refractory Colorectal Liver Metastases

Not yet recruiting

100

RoW

Oxaliplatin, S1, Tegafur,Gimeracil and Oteracil Porassium Capsules, Cetuximab, Metronidazole, Vitamin A, Folic acid

Liaoning Tumor Hospital & Institute

For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method

03/25

ChiCTR2300069000: Total neoadjuvant chemotherapy plus PD-1 antibody in locally advanced gastric or gastro-esophageal junction adenocarcinoma: an open-label, phase 2 trial

Recruiting

Serplulimab 200mg ivdrip q3w+ S-1 40mg/m^2 bid po d1-14 q3w+ Oxaliplatin 130mg/m^2 ivdrip d1 q3w

Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, None

gastric or gastro-esophageal junction adenocarcinoma

NCT04345770: Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer

Recruiting

100

RoW

D2 radical gastrectomy, Surgery, SOX neoadjuvant or postoperative chemotherapy, Chemotherapy, Hyperthermic intraperitoneal chemotherapy (HIPEC), HIPEC

Wuhan University

Malignant Neoplasm of Stomach

03/25

05/25

NCT05583383: A Study of the Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With Camrelizumab+SOX Control Camrelizumab+SOX+ Trastuzumab

Recruiting

RoW

camrelizumab

Henan Cancer Hospital

Advanced Gastric Adenocarcinoma

03/25

NCT05648487: HIPEC Combined With Sintilimab for Gastric Cancer With Peritoneal Metastasis

Not yet recruiting

HIPEC,anti-PD-1 antibody Sintilimab (Tyvyt®), Chemotherapy,Surgery

Affiliated Cancer Hospital & Institute of Guangzhou Medical University

Gastric Cancer

03/25

12/27

NCT04481204: New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

Active, not recruiting

105

Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone''s Chloride, Peyrone''s Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Irinotecan, Leucovorin, Folinic acid, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation

M.D. Anderson Cancer Center, National Cancer Institute (NCI)

Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma

04/25

Double-IA-001, ChiCTR2100041874: DOUBLE-001: a multi-center phase II trial evaluating the effcacy and safety of hepatic infusion of camrelizumab and oxaliplatin plus fluorouracil/ leucovorin combined with sorafenib for advanced hepatocellular carcinoma

Recruiting

198

Arterial Infusion of Camrelizumab ;Arterial Infusion of mFOLFOX ;Oral intake of Sorafenib

Sun Yat-Sen University Cancer Center; Sun Yat-Sen University Cancer Center, Camrelizumab is provided by Jiangsu Hengrui Medicine Co.,Ltd., there is no other funding source.

Hepatocellular carcinoma

CCGLC-010, NCT05839197: A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC

Recruiting

RoW

HAIC, hepatic arterial infusion chemotherapy of FOLFOX, Camrelizumab plus Apatinib

Wan-Guang Zhang

Macrotrabecular Massive Hepatocellular Carcinoma

04/25

ChiCTR2200056808: Terelizumab combined with lenvatinib and GEMOX (gemcitabine plus oxaliplatin) as conversion therapy for unresectable extrahepatic biliary carcinoma

Not yet recruiting

Terelizumab combined with lenvatinib and GEMOX (gemcitabine + oxaliplatin)

The First Medical Center of the People's Liberation Army General Hospital; The First Medical Center of the People's Liberation Army General Hospital, Self-raised

Unresectable extrahepatic biliary carcinoma

ILUSTRO, NCT03505320 / 2017-002566-50: A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of Zolbetuximab (IMAB362) in Participants With Claudin (CLDN) 18.2 Positive, Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gastric or GEJ Adenocarcinoma

Recruiting

143

Europe, Japan, US, RoW

zolbetuximab, IMAB362, oxaliplatin, leucovorin, fluorouracil, Pembrolizumab, folinic acid, nivolumab, Docetaxel

Astellas Pharma Global Development, Inc.

Pharmacokinetics of Zolbetuximab, Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer, Pharmacokinetics of Oxaliplatin, Pharmacokinetics of Fluorouracil Bolus (5-FU)

04/25

12/26

NCT01862315: Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)

Active, not recruiting

Floxuridine (FUDR), dexamethasone, Gemcitabine, Oxaliplatin, MRI, Research blood draws

Memorial Sloan Kettering Cancer Center

Intrahepatic Cholangiocarcinoma, Peripheral Cholangiocarcinoma, Cholangiolar Carcinoma, Cholangiocellular Carcinoma

05/25

BCC-RAD-13, NCT02128100: Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer

Completed

Folfirinox, o Oxaliplatin, o Leucovorin, o Irinotecan, o Fluorouracil, Stereotactic Body Radiation Therapy

University of Louisville, James Graham Brown Cancer Center

Pancreatic Cancer Non-resectable

03/21

SHORT-FOX, NCT04380337: Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer

Active, not recruiting

FOLFOXIRI, FOLFOX regimen, XELOX, IMRT, Intensity-modulated radiotherapy (IMRT)

Stanford University

Rectal Cancer

01/24

01/26

NCT04891289: Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery

Recruiting

164

Gemcitabine, Oxaliplatin, Dexamethasone, Floxuridine (FUDR), Implanted Medical Device

Memorial Sloan Kettering Cancer Center

Intrahepatic Cholangiocarcinoma

05/25

AuspiCiOus, NCT05177133: Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer

Recruiting

Europe

Capecitabine, Xeloda, Oxaliplatin, Oxaliplatin Accord, Retifanlimab, INCMGA00012

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Incyte Corporation

Gastric Adenocarcinoma, Esophageal Adenocarcinoma

05/25

11/29

NCT05920863: Lenvatinib Combined With Tislelizumab and TACE Applied as Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma With High-risk Recurrence Factors

Recruiting

RoW

TACE, Tislelizumab, Lenvatinib

Zhejiang Cancer Hospital

Hepatocellular Carcinoma, Lenvatinib, Tislelizumab, TACE, Pharmorubicin, Oxaliplatin

05/25

03/26

mRCAT, NCT05972655: Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer

Recruiting

RoW

Modified short-course radiotherapy, PD-1 antibody, Capecitabine, Oxaliplatin

Sir Run Run Shaw Hospital

Low Rectal Cancer

05/25

05/26

RECTUM2015, NCT05378919: Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer

Recruiting

250

Europe

Radiotherapy 50 Gy, Fluorouracil/folic acid, Chemotherapy in regimen with Oxaliplatin, fluorouracil, folinic acid (FOLFOX4)

Lithuanian University of Health Sciences

Neoadjuvant Therapy in Rectal Cancer, Radiotherapy, FOLFOX

06/25

06/27

DisTinGuish, NCT04363801: A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

	Oct 2023 - Mar 2024 : Q4'23/Q1'24 - Initial ORR data from DisTinGuish trial for 2L gastric cancer
	Oct 2023 - Dec 2023: Initial data from part C of DisTinGuish trial in combination with tislelizumab for 1L gastric cancer
	Updated data from part B of DisTinGuish trial in combination with tislelizumab for 2L gastric cancer
	Nov 2022 - Nov 2022: Updated data from part B of DisTinGuish trial in combination with tislelizumab for 2L gastric cancer
	ORR, PFS and OS data from DisTinGuish trial in combination with tislelizumab for gastroesophageal junction cancer or gastric cancer
	Sep 2022 - Sep 2022: ORR, PFS and OS data from DisTinGuish trial in combination with tislelizumab for gastroesophageal junction cancer or gastric cancer
	PFS data from part B of DisTinGuish trial in combination with tislelizumab for gastric or gastroesophageal cancer at ASCO-GI 2022
	Jan 2022 - Jan 2022: PFS data from part B of DisTinGuish trial in combination with tislelizumab for gastric or gastroesophageal cancer at ASCO-GI 2022
	Updated positive data from the DisTinGuish study in combination with DKN-01 gastroesophageal junction cancer at ESMO
	Sep 2021 - Sep 2021: Updated positive data from the DisTinGuish study in combination with DKN-01 gastroesophageal junction cancer at ESMO
	ORR data from DisTinGuish trial in combination with tislelizumab for gastric cancer
	Sep 2021 - Sep 2021: ORR data from DisTinGuish trial in combination with tislelizumab for gastric cancer
More

Active, not recruiting

232

Europe, US, RoW

DKN-01 300mg, DKN-01 600mg, DKN-01 400mg, Tislelizumab 200mg, Tislelizumab 400mg, Oxaliplatin, Capecitabine 1000mg/ m2 BID, Xeloda, Leucovorin Calcium, Folinic acid, Fluorouracil

Leap Therapeutics, Inc., BeiGene

Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer

06/25

12/25

NCT04653480: Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC

Recruiting

RoW

Surufatinib, Toripalimab, chemotherapy

Zhejiang University

Colorectal Cancer

06/25

NCT04926467: Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)

Not yet recruiting

Anakinra

Baylor Research Institute

Pancreatic Adenocarcinoma

06/25

06/26

MEND-IT, NCT04838496 / 2020-003134-20: Induction Chemotherapy for Locally Advanced Rectal Cancer

Not yet recruiting

128

Europe

FOLFOXIRI Protocol

Catharina Ziekenhuis Eindhoven, ZonMW

Rectal Cancer

06/25

06/26

ChiCTR2300071844: Envafolimab combined with NSOX (abraxane + oxaliplatin + tegafur gimeraci) regimen for neoadjuvant therapy in gastric cancer: a one-arm, Phase II exploratory clinical trial

Not yet recruiting

Enwollizumab+NSOX

First affiliated hospital of Soochow university; First affiliated hospital of Soochow university, self-finance

gastric cancer

RARE, NCT05941481: Neoadjuvant Chemo-hypoRT Plus PD-1 Antibody (Tislelizumab) in Resectable LA-G/GEJ

Active, not recruiting

RoW

neoadjuvant chemo-hypofractionated radiotherapy plus PD-1 antibody (Tislelizumab)

Jiangsu Cancer Institute & Hospital

Gastric or Gastroesophageal Junction Adenocarcinoma

06/25

12/25

NCT05479240: Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer

Not yet recruiting

Tislelizumab, Capecitabine, oxaliplatin, short-range radiotherapy

Fujian Cancer Hospital

Immunotherapy

06/25

06/28

NCT05364489: Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal Cancer

Not yet recruiting

Bevacizumab combined with Oxaliplatin and TAS-102

The First Affiliated Hospital of Zhengzhou University

Advanced Colorectal Cancer

06/25

06/27

PRIME-RT, NCT04621370: A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer

Not yet recruiting

Durvalumab, MEDI 4736, FOLFOX, mFOLFOX6, Short Course Radiotherapy (Arm A), Long course chemoradiation (Arm B), Capecitabine

Liz-Anne Lewsley, University of Glasgow, AstraZeneca, NHS Greater Glasgow and Clyde

Rectal Cancer, Rectal Adenocarcinoma, Rectal Neoplasms

06/25

12/25

NCT04831528: Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical Study

Not yet recruiting

100

Cetuximab Ab; Bevacizumab; Vermofenib + cetuximab;Trastuzumab+lapatinib or trastuzumab+pertuzumab; others

Fudan University

Metastatic Colorectal Cancer

06/25

06/26

NCT05919095: A Clinical Study of a Preoperative Translational Therapy for Unresectable Gallbladder Cancer

Not yet recruiting

RoW

Carrilizumab plus GEMOX

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Unresectable Gallbladder Cancer

06/25

06/26

ChiCTR2300072773: CAPEOX and bevacizumab combined with or without sintilimab (recombinant fully human anti-programmed death receptor 1 monoclonal antibody) in the first-line conversion therapy for initial unresectable microsatellite stable colorectal cancer liver metastases with RAS mutation or right-sided primary: a randomized, open-label, multi-center phase II study

Not yet recruiting

204

Bevacizumab 7.5mg/kg, administered on the first day, intravenous injection; oxaliplatin 130mg/m^2 administered on the first day, intravenous injection; capecitabine 1g/m^2 twice a day, orally, continuously 14 days, 1 week off, 3 weeks for a cycle ;Bevacizumab 7.5mg/kg, administered on the first day, intravenous injection; oxaliplatin 130mg/m^2 administered on the first day, intravenous injection; capecitabine 1g/m^2 twice a day, orally, continuously 14 days, 1 week off; sintilimab 200mg, administered on the first day, intravenous injection, 3 weeks for a cycle.

Beijing Cancer Hospital; Beijing Cancer Hospital, Innovent Biopharmaceutical (Suzhou) Co., Ltd. will provide sintilimab according to the expected enrollment plan of the research center

Colorectal cancer liver metastases

NCT05957016: Neoadjuvant CIETAI With Concurrent Chemoradiotherapy in Local Advanced Rectal Cancer

Recruiting

RoW

CIETAI-R

Third Military Medical University

Rectal Cancer

06/25

06/26

NCT05353582: Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases

Not yet recruiting

168

RoW

Preoperative systematic therapy, CRS+HIPEC, Postoperative chemotherapy

Sun Yat-sen University

Colorectal Neoplasms, Colorectal Cancer, Colorectal Cancer Metastatic, Peritoneal Metastases, Peritoneal Cancer, Peritoneal Neoplasms, Chemotherapy Effect, Cytoreductive Surgery, Hyperthermic Intraperitoneal Chemotherapy

07/25

NCT05970302: XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC

Recruiting

RoW

Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Tislelizumab, Bevacizumab, Oxaliplatin, Capecitabine, MSS/pMMR, Metastatic Colorectal Cancer (mCRC), RAS-mutated, First-Line

07/25

07/26

NCT05412589: mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC

Recruiting

RoW

mFOLFOX7+Camrelizumab+Apatinib

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Stage III Hepatocellular Cancer (CNLC Staging)

07/25

07/26

NCT06123455: Clinical Study of Taurine Combined With Sintilimab and Chemotherapy for Treatment of Advanced Gastric Cancer

Recruiting

RoW

Taurine, Sintilimab, XELOX regimen, SOX regimen, FOLFOX regimen

Tang-Du Hospital

Gastric Cancer

07/25

EPOC2001, NCT04745988: An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer

Recruiting

Japan

Lenvatinib 20mg, Pembrolizumab, Lenvatinib 8mg, Docetaxel, Oxaliplatin, Levofolinate, Fluorouracil

National Cancer Center Hospital East, Merck Sharp & Dohme LLC

Gastric Cancer

08/25

08/27

NCT05332002: sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)

Recruiting

Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI)

Rutgers, The State University of New Jersey

Gastro-Intestinal Cancer

08/25

ICONIC, NCT05914389: Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer

Recruiting

100

RoW

Oxaliplatin, Capecitabine, Anti-PD-L1 Monoclonal Antibody, Envafolimab, Clostridium butyricum, Colectomy

Second Affiliated Hospital, School of Medicine, Zhejiang University

Colon Neoplasm

08/25

08/30

CAPRI 2 GOIM, NCT05312398: Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen

Active, not recruiting

219

Europe

Cetuximab, Erbitux, FOLFIRI, FOLFOX regimen, FOLFOX, Irinotecan

University of Campania "Luigi Vanvitelli"

Metastatic Colorectal Adenocarcinoma

08/25

06/26

CA209-8TT, NCT03899155 / 2018-004362-34: Pan Tumor Rollover Study

Recruiting

1500

Europe, Canada, Japan, US, RoW

Nivolumab, BMS-936558-01, Ipilimumab, Cabozantinib, Trametinib, Relatlimab, BMS-986016-01, Nivolumab + Relatlimab, BMS-986213, Capecitabine, Bevacizumab, Temozolomide, Rucaparib, Daratumumab, Regorafinib, Leucovorin, Fluorouracil, Oxaliplatin, Enzalutamide, Sunitinib, Pemetrexed, Pembrolizumab

Bristol-Myers Squibb, Exelixis, Novartis, Clovis Oncology, Inc., Janssen Pharmaceuticals

Cancer

08/29

OP-TNT, NCT05563922: Organ Preservation Strategy of Total Neoadjuvant Chemoradiotherapy for Low Rectal Carcinoma

Recruiting

RoW

Total Neoadjuvant Chemoradiotherapy, Total Neoadjuvant Treatment

Shanghai Zhongshan Hospital

Rectal Cancer

08/25

08/27

EDGE-Gastric, NCT05329766: A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies

Jan 2023 - Dec 2024: Data from ARC-21 trial for esophageal adenocarcinoma, gastroesophageal junction and gastric adenocarcinoma

Recruiting

360

Europe, Canada, US, RoW

Domvanalimab, Quemliclustat, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin

Arcus Biosciences, Inc., Gilead Sciences

Gastrointestinal Tract Malignancies

09/26

06/27

METIMMOX-2, NCT05504252: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin

Recruiting

Europe

Nivolumab, Opdivo, Oxaliplatin, 5-fluorouracil, folinic acid

University Hospital, Akershus, Oslo University Hospital, St. Olavs Hospital

Colorectal Adenocarcinoma, Mucinous Adenocarcinoma, Signet Ring Cell Adenocarcinoma

09/25

12/27

NCT05922358: Phase II Study of Reuse of Oxaliplatin Hypersensitivity in Gastrointestinal Tumors

Not yet recruiting

500

Anti-allergic treatment

Fujian Cancer Hospital

Gastrointestinal Tumors

09/25

09/26

NCT06023758: Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC

Recruiting

RoW

KN026, KN046, XELOX

Peking University

HER2-positive Locally Advanced Resectable Gastric Cancer

09/25

12/26

IMPROVE, NCT06120127: Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence

Recruiting

RoW

SBRT, radiotherapy, Chemotherapy, PD-1 antibody, Sintilimab

Fudan University

Radiotherapy, Immunotherapy, Liver Metastases, Colorectal Cancer

09/25

DESTINY-Gastric03, NCT04379596: Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer

	Jul 2023 - Dec 2023: Data from DESTINY-Gastric03 trial for gastric cancer
	Presentation of data from DESTINY-Gastric03 study in HER2-overexpressing gastric cancer at ESMO 2020
	Jul 2020 - Jul 2020: Presentation of data from DESTINY-Gastric03 study in HER2-overexpressing gastric cancer at ESMO 2020

Recruiting

413

Europe, Canada, Japan, US, RoW

Fluorouracil (5-FU), Capecitabine, Durvalumab, MEDI4736, Oxaliplatin, Trastuzumab, Trastuzumab deruxtecan, DS-8201a, Cisplatin, Pembrolizumab, Volrustomig, MEDI5752, Rilvegostomig, AZD2936

AstraZeneca, Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo

Gastric Cancer

07/26

GEMINI-Gastric, NCT05702229 / 2022-002840-29: Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting

240

Europe, Japan, US, RoW

Rilvegostomig, Volrustomig, FOLFOX, XELOX, AZD7789, AZD0901, 5-Fluorouracil, Capecitabine

AstraZeneca, AstraZeneca AB

Gastric Cancer

09/25

03/26

NCT05563012: Short-course Radiotherapy Combined With Neoadjuvant Chemotherapy and PD-1 Inhibitor in the Treatment of Locally Advanced Gastric Adenocarcinoma

Recruiting

RoW

Sintilimal Injection, Capecitabine, Oxaliplatin

Renmin Hospital of Wuhan University

Disorder in Complete Remission in Response to Treatment

10/25

10/26

ERASE-CRC, NCT05062889: Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients

Recruiting

477

Europe

5-Fluorouracil continuous infusion FOLFOXIRI schedule, 5FU, 5-Fluorouracil bolus FOLFOX schedule, 5-Fluorouracil continuous infusion FOLFOX schedule, Oxaliplatin FOLFOX and FOLFOXIRI schedule, Oxa, Oxaliplatin CAPOX schedule, L-Leucovorin, Lederfolin, Capecitabine, Irinotecan, Trifluridine/Tipiracil, FTD/TPI, Trastuzumab, Tucatinib

Gruppo Oncologico del Nord-Ovest, Servier, Foundation Medicine, Seagen Inc.

Stage II Colon Cancer, Stage III Colon Cancer, HER2-positive Colon Cancer, RAS Wild-type Colon Cancer

10/25

12/27

NCT06086197: A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL

Recruiting

RoW

Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin

Zhejiang Cancer Hospital

Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory

10/25

10/26

NCT05239650: Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC

Not yet recruiting

HLX07, HLX10, mFOLFOX6

Shanghai Henlius Biotech

CRC

10/25

10/26

FISSION, NCT06091423: XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study

Recruiting

RoW

XELOX combined with Fruquintinib and Sintilimab

Xiaofeng Chen

Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

11/25

11/26

ZWI-ZW25-201, NCT03929666: A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Active, not recruiting

Canada, US, RoW

ZW25 (Zanidatamab), Capecitabine, Cisplatin, Fluorouracil, Leucovorin, Oxaliplatin, Bevacizumab, Gemcitabine

Jazz Pharmaceuticals

HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

11/25

10/26

RAXO, NCT01531595 / 2011-003137-33: Study of Bevacizumab in Combination With Alternating Xeliri and Xelox in Metastatic Colorectal Cancer

Recruiting

100

Europe

Bevacizumab plus alternating Xelox/Xeliri, Avastin, Xeloda, irinotecan, oxaliplatin

Pia Osterlund

Metastatic Colorectal Cancer

12/25

CHESS, NCT04624958: Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance With Zanubrutinib for Newly-Diagnosed MCL

Recruiting

RoW

Zanubrutinib and Rituximab, PART A, R-DHAOx, PART B, Zanubrutinib Maintenance

Sun Yat-sen University

Mantle Cell Lymphoma, Newly-diagnosed Mantle Cell Lymphoma

12/25

NCT05634590: The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer

Not yet recruiting

RoW

Fruquintinib, FOLFIRI, mFOLFOX6

Fudan University

Metastatic Colorectal Cancer

12/25

BOLSTER, NCT05712356: A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

Recruiting

Europe, US

LSTA1, Durvalumab, Cisplatin, Gemcitabine, FOLFOX regimen, Oxaliplatin, Folinic acid, Fluorouracil, Placebo

Lisata Therapeutics, Inc.

Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Bile Duct Cancer, Gall Bladder Cancer, Gall Bladder Carcinoma

12/25

PRIMUS 001, NCT04151277 / ISRCTN75002153 / 2016-004155-67: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer

Recruiting

500

Europe

FOLFOX-A, Gemcitabe and Abraxane, G-CSF

Judith Dixon-Hughes, NHS Greater Glasgow and Clyde, University of Glasgow

Neoplasms Pancreatic

12/25

01/26

NCT04819971: Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC

Recruiting

RoW

Tirelizumab, Trastuzumab, Docetaxel, S1, Oxaliplatin

The First Affiliated Hospital of Zhengzhou University

Stomach Cancer

12/25

NCT05468138: PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery

Not yet recruiting

141

RoW

SOX, XELOX, Observation, PD-1 antibody

Fudan University

MSI-H, PD-1 Immunotherapy, Gastric Cancer, Adjuvant Therapy

12/25

NCT05515796: Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors

Recruiting

200

RoW

Terelizumab (aka Tislelizumab), CapeOx, Trastuzumab, Radiotherapy

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Immunotherapy, Gastric Cancer, Rectal Cancer, Chemotherapy Effect, Radiotherapy

12/25

ChiCTR2300067295: mHAIC Combined with Lenvatinib and Camrelizumab for Advanced Unresectable HCC: a single-arm prospective, open-label phase II clinical trial

Recruiting

Hepatic artery infusion of oxaliplatin, oral administration of mHAIC in combination with ranvartinib and carlizumab

The Affiliated Hospital of Yanbian University; The Affiliated Hospital of Yanbian University, None

Hepatocellular carcinoma

Miracle-G, NCT06121700: Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer

Recruiting

RoW

Radiotherapy targeted to the primary lesion, Radiotherapy targeted to the metastatic lesions, Anti-PD-1 monoclonal antibody, Trastuzumab, Herceptin®, Chemotherapy, R0 total/subtotal gastrectomy with D2 lymphadenectomy, Metastasectomy, Local ablative therapies

Fudan University

Adenocarcinoma, Stomach Neoplasm, Gastroesophageal-junction Cancer, Oligometastatic Disease, Metastatic Cancer, Metastatic Gastric Cancer, Adenocarcinoma of the Stomach, Gastroesophageal Junction Adenocarcinoma, Metastatic Adenocarcinoma

12/25

12/27

NeoCaCRT, NCT05792735: Neoadjuvant Cadonilimab Plus Chemotherapy Following Short-Course Radiotherapy in Locally Advanced Rectal Cancer

Recruiting

RoW

Cadonilimab Injection, AK104, Short-course radiotherapy, SCRT, Consolidation chemotherapy, mFOLFOX6

Shenzhen People's Hospital, Sixth Affiliated Hospital, Sun Yat-sen University, The University of Hong Kong-Shenzhen Hospital

Locally Advanced Rectal Carcinoma

12/25

12/26

NCT05833672: Neoadjuvant Immunotherapy in Locally Advanced Colon Cancers

Not yet recruiting

100

RoW

Terelizumab, CapeOx

fan li

Colon Cancer, Immunotherapy

12/25

NCT06118658: Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations

Not yet recruiting

RoW

tislelizumab

China Medical University, China

Gastric, Colorectal Adenocarcinoma

12/25

12/26

CEIL, NCT05959356: Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer

Recruiting

198

RoW

Cetuximab + Envafolimab + mFOLFOXIRI, Cetuximab or c225, Envafolimab, Irinotecan, Oxaliplatin, Leucovorin, 5-FU, Cetuximab + mFOLFOX6/FOLFIRI

Sun Yat-sen University

Metastatic Colorectal Cancer

12/25

12/27

NCT05975749: Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer

Recruiting

114

RoW

Serplulimab, Trastuzuma, Chemotherapy

Fudan University

Gastric Cancer

01/26

01/29

LOGICAN, NCT05476796: Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer

Recruiting

118

Europe

Trifluridine/Tipiracil, Lonsurf, Oxaliplatin, FOLFOX regimen, Nivolumab, OPDIVO

UNICANCER, Servier

Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

01/26

01/27

INTENSE, NCT03773367 / 2018-000050-22: Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma.

Active, not recruiting

Europe

Fluorouracil, Oxaliplatin, Irinotecan

Lund University Hospital

Resectable Gastric and Gastroesophageal Junction Adenocarcinoma

05/26



	Diseases Companies Products Productz Mechanisms of Action Sites